Resources

Immunization is a success story for global health and development, saving millions of lives every year at relatively low costs. However, each year, about 20 million infants do not receive the full course of the basic vaccines, with over 50% of them not receiving any vaccines. At the Addis Declaration on Immunization in 2016, African leaders committed to support immunization with the goal of ensuring that every African benefits from immunization.Reflecting on these commitments, PATH set out to assess the progress in the implementation of the Addis Declaration in ten selected countries. A retrospective study on the status of immunization financing, including the factors affecting adequate financing for immunization, was conducted by reviewing secondary data from various sources including global and country-based immunization and health databases and published peer reviewed and gray literature.The following resources include a technical brief detailing the key findings, the full report, and country-specific profiles.

High–quality evidence assessing single–dose HPV vaccination suggests that implementing a single–dose schedule is scientifically sound, and provides the greatest public health benefit.A single–dose HPV vaccination schedule has the potential to reach more girls and avert a greater number of cervical cancer cases than reaching fewer girls with a two–dose regimen.This brief provides a list of frequently asked questions and answers about the evidence around single–dose HPV vaccination, and the current policy landscape.

The World Health Organization recommends the programmatic use of two vaccines, RTS,S/AS01 and R21/Matrix-M, for the prevention of Plasmodium falciparum malaria in children living in malaria-endemic areas—prioritizing areas of moderate and high transmission. More than 28 countries have expressed interest in introducing a malaria vaccine, and most are actively moving toward introduction. This fact sheet reviews the two vaccines side-by-side, to examine how the two products are similar and how they differ to aid in country decision-making.

The World Health Organization (WHO) recommends the programmatic use of two vaccines, RTS,S/AS01 and R21/Matrix-M, for the prevention of Plasmodium falciparum malaria in children living in malaria-endemic areas—prioritizing areas of moderate and high transmission. This fact sheet provides an overview of the evidence that informed WHO to make their recommendation of R21, as well as a summary of the development history of and clinical evidence on R21.

The World Health Organization (WHO) recommends the programmatic use of two vaccines, RTS,S/AS01 and R21/Matrix-M, for the prevention of Plasmodium falciparum malaria in children living in malaria-endemic areas—prioritizing areas of moderate and high transmission. This fact sheet provides an overview of the development history of RTS,S, the impact of and evidence from the RTS,S pilot program conducted in Ghana, Kenya, and Malawi, and recent results from a study on the seasonal use of RTS,S.